title: Successful treatment of relapsing autoimmune thrombotic thrombocytopenic purpura with rituximab.
abstract: Thrombotic thrombocytopenic purpura (TTP) is a rare but life-threatening condition characterized by thrombotic microangiopathy. The standard treatment for TTP is plasmapheresis. For refractory or relapsing cases, various immunosuppressive agents have been tried, and among them rituximab has shown promising results. TTP is rarer in the pediatric age group and the use of rituximab in children with TTP is limited. Reported herein is the successful treatment of relapsing autoimmune TTP with rituximab in a 12-year-old girl.
authors.affiliation: Department of Pediatrics, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA.
authors.forename: Senthilkumar
authors.initials: S
authors.lastname: Sankararaman
authors.affiliation: Department of Pediatrics, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA.
authors.forename: Majed
authors.initials: M
authors.lastname: Jeroudi
authors.affiliation: Department of Pediatrics, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA.
authors.forename: Hassan
authors.initials: H
authors.lastname: Ibrahim
mesh_terms: D002648:Child; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D011697:Purpura, Thrombotic Thrombocytopenic / Q000188:drug therapy*; D000069283:Rituximab / Q000627:therapeutic use*
chemical_list: D007166:Immunosuppressive Agents; D000069283:Rituximab
keywords: ADAMTS13 deficiency; plasma exchange; plasmapheresis; relapse; rituximab; thrombocytopenia; thrombotic thrombocytopenic purpura